A newly published scientific research review that analyzed six studies on the use of the marijuana component cannabidiol to address treatment-resistant epilepsy finds that patients who took CBD experienced a more than a 40 percent average reduction in seizures.

That’s compared to an average reduction of just under 20 percent in patients who received a placebo. This represents a 127% higher response rate for patients who received the intervention.

“Given these results, it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential,” it adds.

Read the full article HERE.